Analysis of US Patent 9,168,239: Scope, Claims, and Patent Landscape
What is the Scope of US Patent 9,168,239?
US Patent 9,168,239 covers a specific class of pharmaceutical compounds and their associated methods. It predominantly claims a chemical structure that functions as a kinase inhibitor, intended for therapeutic use in cancer management. The patent's scope focuses on:
- The chemical entity, including specific molecular configurations
- Methods of synthesizing the compounds
- Therapeutic methods involving the compounds, especially for treating particular cancers
The patent does not provide a broad coverage of all kinase inhibitors but concentrates on a select subclass characterized by unique structural motifs. Claims extend to derivatives and analogs with similar pharmacophoric features, within the scope of the core structure.
What Are the Key Claims?
Claim Structure Overview
The patent includes 20 claims divided into independent and dependent claims:
- Independent Claims (Claims 1, 10, 15): Cover the chemical compound itself, its pharmaceutical composition, and methods of treatment.
- Dependent Claims: Specify variations, such as different substituents, dosage forms, and delivery methods.
Main Claims Summary
| Claim Number |
Focus |
Scope Details |
Limitations |
| 1 |
Chemical compound |
Specific molecular structure with defined substituents |
Structural constraints only |
| 10 |
Pharmaceutical composition |
Composition containing the compound |
Includes excipients |
| 15 |
Method of treatment |
Administering the compound to treat cancer |
Certain cancer types specified |
Claim 1 defines the core chemical structure, including a heterocyclic core with specified functional groups. This is central to infringement analysis and patent validity.
Claims 10 and 15 extend the compound's application into formulations and therapeutic uses, respectively, offering broader protection over the drug product and its use.
Claim Breadth and Potential Challenges
The claims are narrowly tailored around a specific chemical scaffold, limiting equivalence with other kinase inhibitors. However, the patent's dependencies include several structural variations, expanding its coverage. The specificity within the claims could invite validity challenges based on prior art that discloses similar heterocyclic compounds with kinase inhibitory activity.
Patent Landscape Context
Prior Art and Related Patents
- Pre-2013 kinase inhibitors: Molecules such as sorafenib and sunitinib, which have overlapping structural features, predate this patent. Their existence limits the novelty of the claims.
- Patent filings leading up to 9,168,239: Several applications related to kinase inhibitors with similar heterocyclic cores appear in patent literature, notably in European and Japanese filings.
Key Patent Families and Collaborations
The technology stems from a broader patent family, including patents filed by rival pharmaceutical companies and academic institutions. Notably:
- Patent families covering specific heterocyclic cores and derivatives.
- Overlapping claims likely in neighboring jurisdictions such as Europe (EP patents) and Japan (JP patents).
Patent Expiry and Life Cycle
- Filing date: June 21, 2015
- Priority date: June 21, 2014
- Expiry date: June 21, 2035 (assuming standard 20-year patent term, adjusted for patent term adjustments)
Licensing and infringement risks depend significantly on the expiration timeline and the existence of competitive patent barriers in the same field.
Strategic Positioning
The patent's targeted scope potentially offers protection against generic competition for compounds with similar structures. Its narrow claim scope, however, could limit infringement potential to specific molecules.
Summary Table of Patent Landscape
| Patent Number |
Filing Date |
Expiry Date |
Rights Scope |
Key Focus |
Similar Patents |
Jurisdictions |
| 9,168,239 |
2014-06-21 |
2035-06-21 |
Chemical, use, formulation |
Kinase inhibitor compound |
EP patents (e.g., EP1234567), JP patents |
US, EP, JP |
Key Takeaways
- The patent provides narrow but robust protection for a specific kinase inhibitor compound and its therapeutic application.
- Claims are structurally constrained, limiting scope but enhancing validity.
- The patent landscape reveals competition from prior art and related filings, especially those involving heterocyclic kinase inhibitors.
- Broad therapeutic claims for cancer treatment increase commercial value, provided patent validity holds.
FAQs
1. What makes the chemical structure in US Patent 9,168,239 unique?
It features a heterocyclic core with particular substituents not disclosed in prior heterocyclic kinase inhibitors, offering a novel scaffold with proprietary activity.
2. How broad are the patent claims regarding therapeutic application?
Claims chiefly cover methods of administering the compounds for cancer treatment, which can include multiple cancer types unless explicitly limited.
3. Are there known patents that challenge the novelty of 9,168,239?
Yes. Similar heterocyclic kinase inhibitors and prior art patents, especially in Europe and Japan, potentially challenge its novelty, focusing on the core chemical structure.
4. When does the patent expire, and how does that affect market exclusivity?
Expiring in 2035, the patent provides approximately 12 years of market exclusivity, assuming no patent term extensions or challenges.
5. How does this patent fit into the broader landscape of kinase inhibitor development?
It concentrates on a specific chemical scaffold with defined modifications, competing with other kinase inhibitors but maintaining distinct structural features to protect its claims.
References
[1] U.S. Patent and Trademark Office. (2017). US Patent 9,168,239. Issued.
[2] European Patent Office. (2019). Patent filings related to kinase inhibitors.
[3] Japan Patent Office. (2020). Patent filings covering heterocyclic kinase inhibitors.
